MethylGene Inc.

MethylGene Inc.

October 20, 2010 07:31 ET

MethylGene's Lead Program, MGCD265, Nominated "Top Ten Oncology Projects to Watch" by Windhover and Campbell Alliance

MONTREAL, QUEBEC--(Marketwire - Oct. 20, 2010) - MethylGene Inc. (TSX:MYG) announced today that its lead multi-targeted Met kinase inhibitor for oncology, MGCD265, has been selected by Windhover and Campbell Alliance as one of the "Top 10 Most Interesting Oncology Projects to Watch."

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our independent committees considered the most attractive oncology opportunities the industry has to offer," said David Cassak, vice president, content, Windhover Conferences, a division of Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."

MGCD265, MethylGene's lead oncology product candidate, targets the Met, VEGFRs, Tie-2 and Ron receptor tyrosine kinases. To date, MGCD265 has demonstrated an excellent safety profile as well as evidence of clinical activity and pharmacodynamic coverage of the Met target in patient tumor tissue.

"Having the only Met inhibitor on the list this year, we are pleased that the compound's unique attributes have been recognized as a promising therapy and partnering opportunity by Windhover's and Campbell Alliance's prominent selection committee," said Charles Grubsztajn, President and Chief Executive Officer of MethylGene.

In conjunction with MGCD265's inclusion in the "Top 10 to Watch" list, MethylGene has been selected to present at Windhover's Therapeutic Area Partnerships conference which will be held November 2 to 4, 2010 at the Westin Copley Place in Boston, Massachusetts. Additional information on the conference can be found at

About Windhover

Windhover Information Inc., an Elsevier company, has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see

About MGCD265

MGCD265 is a novel, orally active small molecule inhibitor that targets a unique spectrum of receptor tyrosine kinases: Met, VEGFR 1, 2, and 3, Tie-2 and Ron. These kinases play key roles in tumor development, survival and metastasis as well as the inappropriate formation of blood vessels (angiogenesis) that nourish the tumor. MGCD265 is nearing completion of three Phase 1, single-agent and combination clinical trials (with erlotinib and docetaxel) in solid tumors. MGCD265 has an excellent safety profile, either alone or in combination, and has shown preliminary signs of clinical activity. 

About the Met Target

The Met receptor is a protein that is found on the cell's surface. When not properly regulated (i.e. over active) it plays a key role in the growth, metastasis and survival of various types of cancers. Met is also involved in angiogenesis and is most strongly associated with major cancers such as non-small cell lung, colorectal and breast carcinomas.

About MethylGene

MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for fungal infections which has completed Phase 1 clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase 2 clinical trials and is currently in a Phase 2 trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase 1 trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry. Please visit our website at

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management of MethylGene, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond MethylGene's control. These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such results, performance or achievements include, but are not limited to, the timing and effects of regulatory action; the continuation of collaborations; the results of clinical trials; the timing of enrollment or completion of clinical trials; the success, efficacy or safety of MGCD265, MGCD290 or mocetinostat (MGCD0103); the ability to scale up, formulate and manufacture sufficient GMP, clinical or commercialization quantities of MGCD265, MGCD290 or mocetinostat, and the relative success or the lack of success in developing and gaining regulatory approval and/or market acceptance for any compound or new product including MGCD265, MGCD290 or mocetinostat. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, changes in the competitive landscape including changes in the standard of care for the various indications in which MethylGene is involved, and changes to the competitive environment due to consolidation, as well as other risks, as described in MethylGene's Annual Information Form for the fiscal year ending December 31, 2009, under the heading "Risk Factors" which you are urged to read and all other documents filed by the Company that can be found at Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this presentation. These statements speak only as an update on the date they are made and MethylGene is under no obligation to revise such statements as a result of any event, circumstance or otherwise except in accordance with law.

Contact Information